Literature DB >> 21502584

Pharmacogenomics: the genetics of variable drug responses.

Dan M Roden1, Russell A Wilke, Heyo K Kroemer, C Michael Stein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21502584      PMCID： PMC3093198          DOI： 10.1161/CIRCULATIONAHA.109.914820

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  93 in total

Review 1.  Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective.

Authors:  Lawrence J Lesko; Janet Woodcock
Journal:  Nat Rev Drug Discov       Date:  2004-09       Impact factor: 84.694

2.  Opportunities and challenges for the NIH--an interview with Francis Collins. Interview by Robert Steinbrook.

Authors:  Francis Collins
Journal:  N Engl J Med       Date:  2009-09-16       Impact factor: 91.245

3.  Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage.

Authors:  Russell A Wilke; Jason H Moore; James K Burmester
Journal:  Pharmacogenet Genomics       Date:  2005-06       Impact factor: 2.089

4.  The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization.

Authors:  V Dishy; G G Sofowora; H G Xie; R B Kim; D W Byrne; C M Stein; A J Wood
Journal:  N Engl J Med       Date:  2001-10-04       Impact factor: 91.245

5.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

6.  Pharmacogenetic study of statin therapy and cholesterol reduction.

Authors:  Daniel I Chasman; David Posada; Lakshman Subrahmanyan; Nancy R Cook; Vincent P Stanton; Paul M Ridker
Journal:  JAMA       Date:  2004-06-16       Impact factor: 56.272

7.  Stereoselective disposition of carvedilol is determined by CYP2D6.

Authors:  H H Zhou; A J Wood
Journal:  Clin Pharmacol Ther       Date:  1995-05       Impact factor: 6.875

8.  Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.

Authors:  Jean-Philippe Collet; Jean-Sébastien Hulot; Anna Pena; Eric Villard; Jean-Baptiste Esteve; Johanne Silvain; Laurent Payot; Delphine Brugier; Guillaume Cayla; Farzin Beygui; Gilbert Bensimon; Christian Funck-Brentano; Gilles Montalescot
Journal:  Lancet       Date:  2008-12-26       Impact factor: 79.321

9.  Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.

Authors:  L A Siddoway; K A Thompson; C B McAllister; T Wang; G R Wilkinson; D M Roden; R L Woosley
Journal:  Circulation       Date:  1987-04       Impact factor: 29.690

10.  Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.

Authors:  Stuart A Scott; Lisa Edelmann; Ruth Kornreich; Robert J Desnick
Journal:  Am J Hum Genet       Date:  2008-01-17       Impact factor: 11.025
View more
  60 in total

1.  Mapping genes that predict treatment outcome in admixed populations.

Authors:  T M Baye; R A Wilke
Journal:  Pharmacogenomics J       Date:  2010-10-05       Impact factor: 3.550

2.  Genetics and cardiovascular disease: a policy statement from the American Heart Association.

Authors:  Euan A Ashley; Ray E Hershberger; Colleen Caleshu; Patrick T Ellinor; Joe G N Garcia; David M Herrington; Carolyn Y Ho; Julie A Johnson; Steven J Kittner; Calum A Macrae; Gia Mudd-Martin; Daniel J Rader; Dan M Roden; Derek Scholes; Frank W Sellke; Jeffrey A Towbin; Jennifer Van Eyk; Bradford B Worrall
Journal:  Circulation       Date:  2012-05-29       Impact factor: 29.690

3.  Genes and Cardiovascular Disease: Where do we go from here?

Authors:  Sunil K Nadar; Kully Sandhu
Journal:  Sultan Qaboos Univ Med J       Date:  2015-11-23

Review 4.  Cardiovascular pharmacogenomics: current status and future directions.

Authors:  Dan M Roden
Journal:  J Hum Genet       Date:  2015-07-16       Impact factor: 3.172

Review 5.  Clinical association between pharmacogenomics and adverse drug reactions.

Authors:  Zhi-Wei Zhou; Xiao-Wu Chen; Kevin B Sneed; Yin-Xue Yang; Xueji Zhang; Zhi-Xu He; Kevin Chow; Tianxin Yang; Wei Duan; Shu-Feng Zhou
Journal:  Drugs       Date:  2015-04       Impact factor: 9.546

6.  Bayesian estimation of genetic regulatory effects in high-throughput reporter assays.

Authors:  William H Majoros; Young-Sook Kim; Alejandro Barrera; Fan Li; Xingyan Wang; Sarah J Cunningham; Graham D Johnson; Cong Guo; William L Lowe; Denise M Scholtens; M Geoffrey Hayes; Timothy E Reddy; Andrew S Allen
Journal:  Bioinformatics       Date:  2020-01-15       Impact factor: 6.937

Review 7.  Clinical considerations of heritable factors in common heart failure.

Authors:  Thomas P Cappola; Gerald W Dorn
Journal:  Circ Cardiovasc Genet       Date:  2011-12

Review 8.  Mouse Systems Genetics as a Prelude to Precision Medicine.

Authors:  Hao Li; Johan Auwerx
Journal:  Trends Genet       Date:  2020-02-06       Impact factor: 11.639

9.  Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.

Authors:  Özge Saatci; Simone Borgoni; Özge Akbulut; Selvi Durmuş; Umar Raza; Erol Eyüpoğlu; Can Alkan; Aytekin Akyol; Özgür Kütük; Stefan Wiemann; Özgür Şahin
Journal:  Oncogene       Date:  2018-02-02       Impact factor: 9.867

10.  Genotyping NUDT15 can predict the dose reduction of 6-MP for children with acute lymphoblastic leukemia especially at a preschool age.

Authors:  Hisato Suzuki; Hiroko Fukushima; Ryoko Suzuki; Sho Hosaka; Yuni Yamaki; Chie Kobayashi; Aiko Sakai; Kazuo Imagawa; Atsushi Iwabuchi; Ai Yoshimi; Tomohei Nakao; Keisuke Kato; Masahiro Tsuchida; Nobutaka Kiyokawa; Kazutoshi Koike; Emiko Noguchi; Takashi Fukushima; Ryo Sumazaki
Journal:  J Hum Genet       Date:  2016-05-19       Impact factor: 3.172
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.